Sellas Life Sciences to present preclinical SLS009 pancreatic cancer data at AACR meeting in September 2026

SLS•2026-09-02

Focus of the posters

Posters focus on potential anti-tumor activity in patient-derived KRAS-mutant organoids, including MYC-linked vulnerabilities and combination strategies.

The work supports a broader development rationale for SLS009 in solid tumors, signaling continued investment in expansion beyond current late-stage programs.

Preclinical SLS009 pancreatic cancer studies

Sellas announced three preclinical studies of SLS009 (tambiciclib), a CDK9 inhibitor, in pancreatic ductal adenocarcinoma models.

Results will be presented in the future at the AACR Conference on Pancreatic Cancer on Sept. 25-28, 2026, in San Diego.

Sellas Life Sciences to present preclinical SLS009 pancreatic cancer data at AACR meeting in September 2026

Focus of the posters

Preclinical SLS009 pancreatic cancer studies

Related News

Goldman Sachs lifts ADTRAN voting rights stake to 5.95% from 4.89%

Watts Water director Joseph T. Noonan reports disposal of 3,650 common shares worth $1.29 million

Marsh sees US employer health benefit costs rising 8.2% in 2027, highest since 2003

Uber to lay off 10% of staff in biggest cuts since COVID

EVI Industries completes acquisition of garment care firm Sudsies